Kimberly-Clark to Acquire Kenvue in a $48.7 Billion Deal

Kimberly-Clark, the maker of Huggies and Kleenex, announced it has acquired Kenvue–the consumer health company behind Tylenol and Listerine–in a cash-and-stock deal valued at over $40 billion. 

The Details: Including debt, the total value of the transaction is about $48.7 billion, making it one of the largest mergers announced this year. The merger is expected to close in the second half of 2026, pending regulatory review. According to Wall Street Journal (Center bias), the combined company would generate an estimated $32 billion in annual revenue and include ten brands valued at over $1 billion each, ranging from Huggies, Kleenex and Cottonelle to Tylenol and Band-Aid. Kimberly-Clark CEO Mike Hsu said the merger would create “the largest pure-play consumer health company.” 

For Context: Kenvue was created from Johnson & Johnson (J&J) in 2023 as part of a corporate restructuring that separated its consumer health brands from its pharmaceutical and medical device divisions. Since its split from J&J, Kenvue shares have dropped nearly 35% from their initial public offering price. In September, the Trump administration and Health and Human Services Secretary Robert F. Kennedy Jr. advised pregnant women to limit Tylenol use, citing studies that suggest a possible link between the medication and an increased risk of autism in children. Kennedy Jr. later said there is “not sufficient” enough evidence to say Tylenol “definitely” causes autism.

How the Media Covered It: Outlets across the political spectrum contextualized the acquisition within claims linking Tylenol use during pregnancy to autism. CNBC (Lean Left) highlighted the surge in Kenvue's shares following the announcement and the potential impact of the deal on both companies' stocks. It also mentioned the companies' mutual commitment to developing science and technology. Reuters (Center) pointed out skepticism among some investors, who are wary given Kenvue’s recent struggles. It also mentioned the potential legal exposure Kimberly-Clark could face over the alleged links between Tylenol and autism. Just the News (Lean Right) included Kenvue’s response to a recent Texas lawsuit against Tylenol saying it is "deeply concerned by the perpetuation of misinformation.”

Revised by the AllSides staff (of humans) after a first draft by our custom AI. Learn more. Support our mission.